Skip to main content

Advertisement

Table 4 Number of Ellen genes associated with different biological pathways

From: The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures

  Low Risk of Metastasis Genes High Risk of Metastasis Genes Total
Gene Expression 13 2 15
  EGR1, FOS, JUN, NAT10, RPL11, ZFP36, EEF2, LITAF, POLR2E, POLR3E, RPLP2, RPS15, RPS23 RPL38, RPS11  
Proliferation 5 6 11
  KIDINS220, PIK3R1, ZFP36L2, CDIPT, CXCL12 JTB, SERPINB3, NUCKS1, SNRPE, SPDEF, TXN  
Immune Response 5 3 8
  FOS, CXCL12, HLA-DPA1, JAK1, PCBP2 FKBP4, MTDH, NUCKS1  
Cell Migration 3 4 7
  SPTBN1, CYFIP1, CXCL12 S100P, ARF6, CSTA, NUCKS1  
Apoptosis 6 1 7
  JUN, SGK1, LITAF, TNFRSF10B, GLTSCR2, ITM2B S100G(-)  
Stress Response 5 0 5
  DUSP1, ABAT, CIRBP, GLTSCR2, GPX4   
Metabolism 1 4 5
  GPX4 FLOT1, SQLE, COX5B, GPR172A  
Epigenetics 2 2 4
  NCOR1, SMARCA2 NAT10, H3F3A  
Angiogenesis 0 2 2
   ACTC1, MB  
Differentiation 2 0 2
  DPYSL2, RAI2   
Cell Cycle 0 1 1
   SFN  
PTM and Trafficking 1 0 1
  DUSP1   
Cytoskeleton 0 1 1
   KRT10